KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bristol Myers Squibb (BMY) Gross Margin (2016 - 2025)

Historic Gross Margin for Bristol Myers Squibb (BMY) over the last 17 years, with Q4 2025 value amounting to 67.23%.

  • Bristol Myers Squibb's Gross Margin rose 62200.0% to 67.23% in Q4 2025 from the same period last year, while for Dec 2025 it was 71.08%, marking a year-over-year change of 0.0%. This contributed to the annual value of 71.08% for FY2025, which is 0.0% changed from last year.
  • Per Bristol Myers Squibb's latest filing, its Gross Margin stood at 67.23% for Q4 2025, which was up 62200.0% from 71.89% recorded in Q3 2025.
  • Bristol Myers Squibb's Gross Margin's 5-year high stood at 80.34% during Q4 2021, with a 5-year trough of 61.01% in Q4 2024.
  • For the 5-year period, Bristol Myers Squibb's Gross Margin averaged around 75.02%, with its median value being 75.69% (2023).
  • As far as peak fluctuations go, Bristol Myers Squibb's Gross Margin skyrocketed by 83100bps in 2021, and later tumbled by -150700bps in 2024.
  • Bristol Myers Squibb's Gross Margin (Quarter) stood at 80.34% in 2021, then decreased by -4bps to 77.27% in 2022, then decreased by -2bps to 76.08% in 2023, then decreased by -20bps to 61.01% in 2024, then increased by 10bps to 67.23% in 2025.
  • Its last three reported values are 67.23% in Q4 2025, 71.89% for Q3 2025, and 72.52% during Q2 2025.